NG2 confers GC resistance to MLLr B-ALL cells. (A) Primary NG2^POS and NG2^NEG MLLr B-ALL cells were FACS sorted and treated with increasing concentrations of dexamethasone (DX), vincristine (VCR), and L-asparaginase (L-Asp) alone or in combination (standard induction therapy, VXL). Percentage of live cells (7-aminoactinomycin D stain (7AAD)^-/annexin^- population by FACS) is shown for each treatment. Top panel shows a representative FACS dot plot of NG2 expression in leukemic cells from a patient with MLLr B-ALL. (B) Percentage of live cells in wild-type (NG2^WT) and CRISPR-Cas9 knocked out (NG2^KO) SEM cells treated as above. Top panel shows an immunoblot of NG2 protein levels in NG2^WT and NG2^KO SEM cells. (C) Experimental design for in vivo treatments using NG2^WT and NG2^KO SEM cells. (D) Percentage of SEM cells detected in transplanted mice at the end of treatment (day 13) in the indicated groups. Each point depicts a mouse. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, unpaired Student t test. Ns, not significant.